Mast cell density and its clinical relevance in Waldenström's macroglobulinemia.
Waldenström's macroglobulinemia
mast cells
tumor biology
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
15
12
2021
revised:
27
12
2021
accepted:
29
12
2021
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
The presence of numerous mast cells (MCs) mixed with tumor cells in the bone marrow (BM) is a hallmark of the diagnosis of Waldenström's macroglobulinemia (WM). MCs have been shown to support lymphoplasmacytic cell growth, but there is thus far no demonstration of the prognostic impact of BM MC density in WM. We investigated BM MC density by sensitive and specific digital quantification, allowing the analysis of a large area infiltrated by BM tumor cells. A total of 65 WM patients were investigated, including 54 at diagnosis and 11 at relapse. Tryptase and CD20 immunohistochemisty staining was performed on contiguous sections of deparaffinized BM trephine biopsies. After numerization of each section, the BM surface area was manually marked out, excluding the bone framework and adipocytes to limit the analyses to only hematopoietic tissue. MCs were assessed using a digital tool previously used to quantify immune-cell infiltrates on tumor-tissue sections. Deep next-generation sequencing and allele-specific PCR were used to explore the
Identifiants
pubmed: 35846063
doi: 10.1002/jha2.378
pii: JHA2378
pmc: PMC9176068
doi:
Types de publication
Journal Article
Langues
eng
Pagination
371-378Informations de copyright
© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Acta Haematol. 1950 Dec;4(6):374-83
pubmed: 14810487
Am J Clin Pathol. 1981 Jan;75(1):34-8
pubmed: 7457427
Int Arch Allergy Immunol. 2015;168(4):263-8
pubmed: 26894886
J Clin Pathol. 1972 Jan;25(1):12-6
pubmed: 4622624
Br J Haematol. 2007 Jul;138(1):68-71
pubmed: 17555448
N Engl J Med. 2012 Aug 30;367(9):826-33
pubmed: 22931316
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Eur J Haematol. 2016 Mar;96(3):252-9
pubmed: 25963595
Immunol Rev. 2018 Mar;282(1):121-150
pubmed: 29431212
Hematol Oncol Clin North Am. 2018 Oct;32(5):753-763
pubmed: 30190015
Br J Haematol. 2002 Oct;119(1):122-4
pubmed: 12358914
Blood. 2008 May 1;111(9):4664-7
pubmed: 18309035
Blood. 2014 Mar 13;123(11):1637-46
pubmed: 24366360
Acta Haematol. 1958 Jul-Oct;20(1-4):33-9
pubmed: 13582544
Semin Oncol. 2003 Apr;30(2):110-5
pubmed: 12720118
Am J Pathol. 2010 Aug;177(2):792-802
pubmed: 20595635
Leuk Lymphoma. 2010 Oct;51(10):1779-92
pubmed: 20795787
Blood. 2014 May 1;123(18):2791-6
pubmed: 24553177
Am J Med. 1982 Oct;73(4):539-42
pubmed: 6957149
Tumour Biol. 2015 Nov;36(11):8491-7
pubmed: 26026586
Blood. 2014 Mar 20;123(12):1836-49
pubmed: 24452203
Clin Cancer Res. 2017 Oct 15;23(20):6325-6335
pubmed: 28754818
Clin Cancer Res. 2016 Mar 15;22(6):1480-8
pubmed: 26490317
Front Immunol. 2017 Apr 12;8:424
pubmed: 28446910
Ann Oncol. 2006 Aug;17(8):1275-82
pubmed: 16788002
Br J Haematol. 2013 Jan;160(2):171-6
pubmed: 23150997
Blood. 2012 Sep 6;120(10):2042-54
pubmed: 22837530